Colorectal cancer screening refers to the practice of detecting pre-cancerous polyps or growths in the colon and rectum through screening tests or examinations. Colorectal cancer is one of the most commonly diagnosed cancers in the U.S., affecting over 150,000 Americans each year. Screening allows for the detection of colorectal cancer in its early stages, when treatment can be much less invasive and more effective. Common screening tests include fecal immunochemical tests, computed tomographic colonography, sigmoidoscopy, and colonoscopy. Advances in screening technologies have made early detection easier and less invasive for patients.

The Global Colorectal Cancer Screening Market Size is estimated to be valued at US$ 5,952.2 Mn in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. Colorectal Cancer Screening are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, and Novigenix SA Among Others. Several major players are focusing on developing advanced screening technologies such as biomarker tests, capsule colonoscopies, and newer imaging modalities to detect polyps and tumors at an early stage. This is expected to present lucrative growth opportunities for market players over the forecast period.

On the technological front, new non-invasive screening tests such as Cologuard, an at-home fecal immunochemical test, have gained popularity in recent years. Advances are also being made in DNA sequencing and liquid biopsy technologies to detect tumor DNA in blood samples, providing an alternative screening method. Researchers are further exploring the potential of artificial intelligence and machine learning algorithms to analyze medical images and detect signs of cancer. These technological advancements are expanding screening options and expected to drive market growth.

Market Drivers: Early detection rates remain low in the U.S. despite screening guidelines, representing a major market driver. Only around 65% of Americans are up-to-date with colorectal cancer screening as recommended. To improve patient compliance and uptake of screening, continued efforts are required to increase awareness, enable access to screening, and develop novel non-invasive tests. Advancements lowering procedural complexity, cost and risk are also fueling demand. Rising treatment costs of colorectal cancer in later stages serve as an economic incentive for preventative screening.

Current challenges in U.S. Colorectal Cancer Screening industry:

The U.S. colorectal cancer screening market faces various challenges. Majority of the population is still unaware about the importance and benefits of regular screening. Lack of awareness and knowledge leads to low screening rates in the country. Hesitation and fear of screening procedures and tests is another roadblock. For asymptomatic people, the notion of getting screened without any symptoms deters them from screening. Cost of different screening options poses financial challenges to many. Insurance coverage and lack of insurance among some sections hamper screening adoption.

Swot Analysis

Strength: Growing awareness campaigns by healthcare providers and organizations have increased screening rates in recent years. Various low-cost screening options are available.

Weakness: Underpenetration in rural areas due to limited accessibility and infrastructure. High false positive rates of certain non-invasive screening tests cause unnecessary anxiety.

Opportunity: Rising healthcare expenditures and expanding insurance coverage are conducive to market growth. Newer non-invasive screening tests in pipeline can boost the uptake.

Threats: Shortage of trained professionals impacts timely and high-quality screening. Growing preference for alternative treatment options like immunotherapy limits overall market potential.

The U.S. East North Central region presently accounts for the largest share of the colorectal cancer screening market value owing to high screening rates and healthcare spending in states like Ohio, Illinois and Michigan. The South Atlantic region encompassing states like Florida and North Carolina is poised to witness the fastest market growth during the forecast period on account of aging population, cancer awareness drives and favorable reimbursement scenario.

What Are The Key Data Covered In This U.S. Colorectal Cancer Screening Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the U.S. Colorectal Cancer Screening Market’s growth between 2024 and 2031.

:- Accurate calculation of the size of the U.S. Colorectal Cancer Screening Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- U.S. Colorectal Cancer Screening Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of U.S. Colorectal Cancer Screening Market vendors

FAQ’S

Q.1 What are the main factors influencing the U.S. Colorectal Cancer Screening market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top U.S. Colorectal Cancer Screening Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the U.S. Colorectal Cancer Screening market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

The post U.S. Colorectal Cancer Screening Market is Estimated to Witness High Growth Owing to Technological Advancements in Early Cancer Detection appeared first on .